Skip to Content

Elexacaftor / ivacaftor / tezacaftor Pregnancy and Breastfeeding Warnings

Elexacaftor / ivacaftor / tezacaftor is also known as: Trikafta

Medically reviewed by Drugs.com. Last updated on Feb 12, 2021.

Elexacaftor / ivacaftor / tezacaftor Pregnancy Warnings

Benefit should outweigh risk

US FDA pregnancy category: Not assigned

Risk Summary: Data is limited and incomplete with use of this combination drug or its individual components to inform a drug-related pregnancy risk; reproductive and developmental studies in rats and rabbits have not shown teratogenicity or adverse developmental effects.

While there are no animal studies with concomitant administration of all 3 agents, there are animal studies with the individual agents. Placental transfer of elexacaftor, tezacaftor, and ivacaftor has been observed in pregnant rats; placental transfer of ivacaftor has been observed in pregnant rabbits. Elexacaftor administration to pregnant rats and rabbits during organogenesis demonstrated no teratogenicity or adverse developmental effects at doses that produced maternal exposures up to approximately 2 times the maximum recommended human dose (MRHD) in rats and 4 times the MRHD in rabbits. Tezacaftor administration during organogenesis at doses approximating maternal exposures of up to 3 times (pregnant rats) and 0.2 times (pregnant rabbits) the MRHD revealed no teratogenicity or adverse developmental effects. Ivacaftor administration in rats and rabbits at doses approximating 5 and 14 times MRHD, respectively also revealed no teratogenicity or adverse developmental effects on pups. No adverse developmental effects were observed with administration of elexacaftor or tezacaftor at 1 time the MRHD or ivacaftor at 3 times the MRHD to pregnant rats from organogenesis through lactation. There are no controlled data in human pregnancy.

US FDA pregnancy category Not Assigned: The US FDA has amended the pregnancy labeling rule for prescription drug products to require labeling that includes a summary of risk, a discussion of the data supporting that summary, and relevant information to help health care providers make prescribing decisions and counsel women about the use of drugs during pregnancy. Pregnancy categories A, B, C, D and X are being phased out.

See references

Elexacaftor / ivacaftor / tezacaftor Breastfeeding Warnings

There is limited information on the use of elexacaftor, tezacaftor or ivacaftor during breastfeeding and the effects on the breastfed infant, or the effects on milk production. Lacteal excretion has been demonstrated with each component to lactating dams; exposure in rat milk has been estimated to be approximately 0.4, 3, and 1.5 times higher than plasma for elexacaftor, tezacaftor and ivacaftor, respectively. A task force of respiratory experts has looked at these drugs and feels they are probably safe during breastfeeding. Until more data is available, it is important to weigh the developmental and health benefits of breastfeeding along with the mother's clinical need for this drug against any potential adverse effects on the breastfed child from this drug or from the underlying maternal condition.

Benefit should outweigh risk

Excreted into human milk: Elexacaftor (Unknown); Ivacaftor (Yes); Tezacaftor (Unknown)
Excreted into animal milk: Elexacaftor (Yes); Ivacaftor (Yes); Tezacaftor (Yes)

Comments:
-Until more data are available, it may be advisable to monitor bilirubin and liver enzymes of breastfed infants, as well as examine breastfed infants for cataracts.

See references

References for pregnancy information

  1. "Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor)." Vertex Pharmaceuticals, Cambridge, MA.

References for breastfeeding information

  1. United States National Library of Medicine "Toxnet. Toxicology Data Network. Available from: URL: http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT." ([cited 2013 -]):
  2. "Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor)." Vertex Pharmaceuticals, Cambridge, MA.
  3. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.